-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
AffaMed Therapeutics (hereinafter referred to as “AffaMed”), a clinical-stage innovative biopharmaceutical company dedicated to meeting the needs of patients with global ophthalmology, neurological and psychiatric diseases, held a grand ceremony on October 28 to celebrate its partnership with SIFI SpA, a leading international ophthalmology company (hereinafter referred to as A joint venture company established by "SIFI" —Aishen Medical Technology (Beijing) Co.
, Ltd.
(hereinafter referred to as "Aishen Medical") was formally established
.
The newly established Aichen Medical will further promote the development, production and sales of innovative high-quality intraocular lens ("IOL") products in the Greater China market
AffaMed Medical Technology (Beijing) Co.
, Ltd.
Speech by Chairman Song Ruilin, China Association for the Promotion of Pharmaceutical Innovation
Address by Professor Sun Xinghuai, the chairman-designate of the Chinese Medical Ophthalmology Branch
Speech by Deputy Director Wang Lixun, Beijing Municipal Bureau of Economy and Information Technology
Dr.
Dayao Zhao, CEO of AffaMed, said: “As another milestone in the development of AffaMed’s business, the establishment of AffaMed has accelerated the introduction of high-quality Italian intraocular lenses to Greater China, which shows that we have taken another critical step towards achieving our strategic goals
.
Lens is the main treatment for cataract surgery.
At the ceremony, Mr.
Fabrizo Chines, CEO of SIFI, the joint venture partner, also sent congratulations via video
.
Mr.
Dr.
Han Yi, General Manager of Aim Medical, said: "At present, Aim Medical currently has the exclusive rights of several high-quality EDOF extended depth-of-field intraocular lenses in Greater China
.
We hope to accelerate the clinical progress of these products and bring them to Chinese patients as soon as possible.
The guests at the conference jointly launched a bright future for Aichen Medical
Aichen Medical currently owns the exclusive rights of MINI WELL®, MINI WELL TORIC® and MINI WELL PROXA® series of extended depth-of-field ("EDOF") intraocular lenses
.
As the industry's leading solution in cataract refractive surgery, these intraocular lens products can effectively correct refractive errors, presbyopia, and astigmatism, and help patients obtain high-quality naked vision at different distances and light conditions
